TMDX
TransMedics Group IncNASDAQHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$3.75B
P/E Ratio
22.46
EPS
$4.87
Beta
2.08
52W High
$156.00
52W Low
$75.50
50-Day MA
$126.97
200-Day MA
$124.09
Dividend Yield
—
Profit Margin
31.40%
Forward P/E
43.86
PEG Ratio
—
About TransMedics Group Inc
TransMedics Group, Inc., a commercial-stage medical technology company, is dedicated to transforming organ transplant therapy for patients with end-stage organ failure in the United States and internationally. The company is headquartered in Andover, Massachusetts.
Fundamentals
| Revenue (TTM) | $605.49M |
| Gross Profit (TTM) | $362.81M |
| EBITDA | $134.47M |
| Operating Margin | 13.20% |
| Return on Equity | 54.20% |
| Return on Assets | 7.25% |
| Revenue/Share (TTM) | $17.81 |
| Book Value | $13.81 |
| Price-to-Book | 7.93 |
| Price-to-Sales (TTM) | 6.20 |
| EV/Revenue | 6.25 |
| EV/EBITDA | 25.47 |
| Quarterly Earnings Growth (YoY) | 1188.00% |
| Quarterly Revenue Growth (YoY) | 32.20% |
| Shares Outstanding | $34.30M |
| Float | $33.13M |
| % Insiders | 2.99% |
| % Institutions | 111.30% |
Historical Volatility
HV 10-Day
55.07%
HV 20-Day
56.50%
HV 30-Day
61.48%
HV 60-Day
52.92%
HV Rank
75.0%
Volatility is currently contracting
Analyst Ratings
Consensus ($156.10 target)
2
Strong Buy7
Buy2
HoldData last updated: 4/9/2026